Impax Laboratories Company Profile (NASDAQ:IPXL)

About Impax Laboratories (NASDAQ:IPXL)

Impax Laboratories logoImpax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:IPXL
  • CUSIP: 45256B10
  • Web: www.impaxlabs.com
Capitalization:
  • Market Cap: $1.09 billion
  • Outstanding Shares: 71,597,000
Average Prices:
  • 50 Day Moving Avg: $14.46
  • 200 Day Moving Avg: $13.18
  • 52 Week Range: $7.75 - $35.24
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 13.62
  • P/E Growth: 2.49
Sales & Book Value:
  • Annual Revenue: $783.32 million
  • Price / Sales: 1.39
  • Book Value: $7.55 per share
  • Price / Book: 2.02
Profitability:
  • EBIDTA: $148.9 million
  • Net Margins: -19.93%
  • Return on Equity: 11.34%
  • Return on Assets: 5.99%
Debt:
  • Debt-to-Equity Ratio: 0.90%
  • Current Ratio: 2.09%
  • Quick Ratio: 1.59%
Misc:
  • Average Volume: 2.48 million shs.
  • Beta: 1.32
  • Short Ratio: 1.32
 

Frequently Asked Questions for Impax Laboratories (NASDAQ:IPXL)

What is Impax Laboratories' stock symbol?

Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."

How were Impax Laboratories' earnings last quarter?

Impax Laboratories Inc (NASDAQ:IPXL) released its earnings results on Wednesday, May, 10th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.12 by $0.01. The company earned $184.40 million during the quarter, compared to analyst estimates of $193.17 million. Impax Laboratories had a negative net margin of 19.93% and a positive return on equity of 11.34%. The company's revenue for the quarter was down 18.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.43 EPS. View Impax Laboratories' Earnings History.

What guidance has Impax Laboratories issued on next quarter's earnings?

Impax Laboratories updated its FY17 earnings guidance on Wednesday, May, 10th. The company provided EPS guidance of $0.55-0.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.71.

Where is Impax Laboratories' stock going? Where will Impax Laboratories' stock price be in 2017?

13 brokers have issued 12-month price targets for Impax Laboratories' shares. Their predictions range from $7.00 to $62.00. On average, they expect Impax Laboratories' stock price to reach $23.92 in the next twelve months. View Analyst Ratings for Impax Laboratories.

What are analysts saying about Impax Laboratories stock?

Here are some recent quotes from research analysts about Impax Laboratories stock:

  • 1. According to Zacks Investment Research, "Impax’s Generics segment has been under competitive and pricing pressure which is expected to persist in 2017. Shares of Impax have outperformed the Generics-Drugs industry in year to date. The company did not provide any revenue or earnings guidance for 2017 due to ongoing revenue volatility within the company's Generics division. However, Impax’s generics pipeline should be able to take advantage of the upcoming patent expiries in the pharma industry. The acquisition of several generic products in Aug 2016 including 15 currently marketed products bode positive for the company. The company is taking steps to reduce costs and improve efficiencies which is expected to produce annual savings in the range of $40 million and $50 million by 2018. Estimate movement has been mixed lately ahead of the Q1 earnings results. Impax has a negative record of earnings surprises in recent quarters." (5/8/2017)
  • 2. Guggenheim analysts commented, "Impax (IPXL, BUY, $12.70) named Paul Bisaro as its new, full-time CEO earlier today, which increases our confidence that there could be upside to consensus expectations in '17+. Bisaro has 25 years of generic and branded pharma experience, with an impressive track record of execution and transformation at companies like Allergan (AGN, NEUTRAL, $237.33) and its predecessors and Barr Pharmaceuticals (acquired by TEVA [BUY, $32.76] in 2010). Bisaro is also on the Board of Directors of AGN and Zoetis (ZTS, BUY, $53.85)." (3/27/2017)
  • 3. Royal Bank of Canada analysts commented, "The stock was down -35% following IPXL's 4Q results and first-time 2017 update (no revenue or EPS given, as expected). We continue to see a number of generic headwinds that will linger as IPXL pursues a leadership change and what we see as needed review of strategic positioning. We lower EPS and target to reflect continued challenges. Remain Sector Perform." (3/2/2017)
  • 4. BMO Capital Markets analysts commented, "an opportunistic one for IPXL and could drive some upside to our Adrenaclick forecasts." (1/13/2017)

Are investors shorting Impax Laboratories?

Impax Laboratories saw a increase in short interest during the month of May. As of May 15th, there was short interest totalling 10,442,899 shares, an increase of 20.7% from the April 28th total of 8,651,398 shares. Based on an average daily trading volume, of 2,615,696 shares, the short-interest ratio is currently 4.0 days. Approximately 14.5% of the company's shares are sold short.

Who are some of Impax Laboratories' key competitors?

Who owns Impax Laboratories stock?

Impax Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.74%), North Tide Capital LLC (4.19%), Dimensional Fund Advisors LP (3.69%), Frontier Capital Management Co. LLC (1.55%), Point72 Asset Management L.P. (1.53%) and GW&K Investment Management LLC (1.09%). Company insiders that own Impax Laboratories stock include Leslie Z Benet, Mark A Schlossberg, Michael Markbreiter, Michael Nestor and Peter R Terreri. View Institutional Ownership Trends for Impax Laboratories.

Who sold Impax Laboratories stock? Who is selling Impax Laboratories stock?

Impax Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Nomura Holdings Inc., UBS Group AG, Renaissance Technologies LLC, Cornerstone Capital Management Holdings LLC., Goldman Sachs Group Inc., Tudor Investment Corp ET AL, ProShare Advisors LLC and TIAA CREF Investment Management LLC. Company insiders that have sold Impax Laboratories stock in the last year include Leslie Z Benet and Michael Nestor. View Insider Buying and Selling for Impax Laboratories.

Who bought Impax Laboratories stock? Who is buying Impax Laboratories stock?

Impax Laboratories' stock was acquired by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, North Tide Capital LLC, Dimensional Fund Advisors LP, Point72 Asset Management L.P., Fosun International Ltd, Vanguard Group Inc., Oxford Asset Management and Thrivent Financial For Lutherans. View Insider Buying and Selling for Impax Laboratories.

How do I buy Impax Laboratories stock?

Shares of Impax Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Impax Laboratories stock cost?

One share of Impax Laboratories stock can currently be purchased for approximately $15.25.

Analyst Ratings

Consensus Ratings for Impax Laboratories (NASDAQ:IPXL) (?)
Ratings Breakdown: 2 Sell Ratings, 7 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.15)
Consensus Price Target: $23.92 (56.87% upside)

Analysts' Ratings History for Impax Laboratories (NASDAQ:IPXL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017Royal Bank of CanadaReiterated RatingOutperform$10.00 -> $62.00MediumView Rating Details
4/5/2017Deutsche Bank AGSet Price TargetBuy$11.00 -> $15.00HighView Rating Details
3/27/2017GuggenheimReiterated RatingBuy$20.00LowView Rating Details
3/8/2017Susquehanna Bancshares IncDowngradePositive -> Neutral$18.00 -> $10.00LowView Rating Details
3/1/2017Piper Jaffray CompaniesDowngradeNeutral -> Underweight$7.00N/AView Rating Details
1/13/2017BMO Capital MarketsReiterated RatingSell -> Market Perform$18.00N/AView Rating Details
12/28/2016Janney Montgomery ScottInitiated Coverageinit -> Neutral$15.00N/AView Rating Details
11/14/2016WallachBeth CapitalDowngradeBuy -> Hold$30.00 -> $18.00N/AView Rating Details
11/7/2016Bank of America CorpDowngradeNeutral -> Underperform$19.00N/AView Rating Details
9/27/2016Goldman Sachs Group IncUpgradeSell -> Neutral$25.00 -> $26.00N/AView Rating Details
8/15/2016Northland SecuritiesUpgradeMarket Perform -> Outperform$30.00N/AView Rating Details
8/10/2016Leerink SwannLower Price TargetMarket Perform$33.00 -> $24.00N/AView Rating Details
6/1/2016JPMorgan Chase & Co.Initiated CoverageNeutral$47.00N/AView Rating Details
4/15/2016BTIG ResearchReiterated RatingBuy$48.00N/AView Rating Details
3/2/2016NomuraReiterated RatingHoldN/AView Rating Details
2/17/2016Raymond James Financial, Inc.UpgradeUnderperform -> Market PerformN/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Impax Laboratories (NASDAQ:IPXL)
Earnings by Quarter for Impax Laboratories (NASDAQ:IPXL)
Earnings History by Quarter for Impax Laboratories (NASDAQ:IPXL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017$0.12$0.11$193.17 million$184.40 millionViewN/AView Earnings Details
3/1/2017Q416$0.16$0.16$219.54 million$198.40 millionViewListenView Earnings Details
11/9/2016Q316$0.40$0.37$234.87 million$228.00 millionViewListenView Earnings Details
8/9/2016Q216$0.32$0.21$223.67 million$173.00 millionViewN/AView Earnings Details
5/10/2016Q116$0.39$0.43$241.84 million$226.00 millionViewListenView Earnings Details
2/22/2016Q415$0.44$0.62$223.23 million$282.10 millionViewListenView Earnings Details
11/9/2015Q315$0.39$0.40$214.69 million$221.10 millionViewN/AView Earnings Details
8/10/2015Q215$0.35$0.34$200.68 million$214.20 millionViewListenView Earnings Details
5/11/2015Q115$0.18$0.09$146.00 million$143.10 millionViewListenView Earnings Details
2/24/2015Q414$0.11$0.16$125.50 million$131.20 millionViewN/AView Earnings Details
11/4/2014Q314$0.31$0.33$148.36 million$145.63 millionViewN/AView Earnings Details
8/6/2014Q214$0.39$0.60$155.97 million$188.10 millionViewN/AView Earnings Details
5/1/2014Q114$0.13$0.24$97.80 million$118.70 millionViewN/AView Earnings Details
2/20/2014Q413$0.03($0.14)$119.01 million$100.74 millionViewN/AView Earnings Details
11/4/2013Q313($0.08)$0.25$111.83 million$115.75 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.04$0.08$120.75 million$129.63 millionViewN/AView Earnings Details
5/1/2013Q1 2013$0.21$0.37$129.12 million$148.50 millionViewN/AView Earnings Details
2/25/2013Q4 2012$0.19$0.30$127.03 million$141.10 millionViewN/AView Earnings Details
10/30/2012Q312$0.49$0.48$160.76 million$145.60 millionViewN/AView Earnings Details
7/31/2012$0.44$0.60ViewN/AView Earnings Details
5/1/2012$0.45$0.52ViewN/AView Earnings Details
2/28/2012$0.19$0.33ViewN/AView Earnings Details
11/1/2011$0.20$0.30ViewN/AView Earnings Details
8/2/2011$0.18$0.19ViewN/AView Earnings Details
5/3/2011$0.15$0.21ViewN/AView Earnings Details
2/24/2011$0.22$0.23ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Impax Laboratories (NASDAQ:IPXL)
2017 EPS Consensus Estimate: $0.87
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.13$0.13$0.13
Q2 20171$0.17$0.17$0.17
Q3 20171$0.22$0.22$0.22
Q4 20171$0.35$0.35$0.35
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Impax Laboratories (NASDAQ:IPXL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Impax Laboratories (NASDAQ:IPXL)
Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 84.47%
Insider Trades by Quarter for Impax Laboratories (NASDAQ:IPXL)
Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)
Insider Trades by Quarter for Impax Laboratories (NASDAQ:IPXL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/17/2017Michael NestorInsiderSell857$16.48$14,123.36View SEC Filing  
5/12/2017Michael NestorInsiderSell700$17.11$11,977.00View SEC Filing  
8/15/2016Leslie Z BenetDirectorSell10,092$22.81$230,198.52View SEC Filing  
9/11/2015Mark A SchlossbergSVPSell7,457$43.30$322,888.10View SEC Filing  
9/10/2015Michael NestorInsiderSell5,000$43.56$217,800.00View SEC Filing  
8/31/2015Michael MarkbreiterDirectorSell28,000$41.70$1,167,600.00View SEC Filing  
8/27/2015Mark A SchlossbergSVPSell4,649$43.41$201,813.09View SEC Filing  
8/27/2015Peter R TerreriDirectorSell4,833$43.93$212,313.69View SEC Filing  
8/26/2015Michael MarkbreiterDirectorSell19,399$42.24$819,413.76View SEC Filing  
6/6/2014Larry HsuDirectorSell100,000$28.38$2,838,000.00View SEC Filing  
5/27/2014Peter R TerreriDirectorSell3,000$28.00$84,000.00View SEC Filing  
5/22/2014Larry HsuDirectorSell50,000$27.22$1,361,000.00View SEC Filing  
5/21/2014Larry HsuDirectorSell3,800$26.53$100,814.00View SEC Filing  
5/16/2014Nigel FlemingDirectorSell1,900$25.72$48,868.00View SEC Filing  
5/12/2014Nigel FlemingDirectorSell1,333$26.58$35,431.14View SEC Filing  
5/8/2014Michael MarkbreiterDirectorSell12,500$26.44$330,500.00View SEC Filing  
5/6/2014Larry HsuDirectorSell219,386$26.28$5,765,464.08View SEC Filing  
3/11/2014Michael MarkbreiterDirectorSell4,000$27.54$110,160.00View SEC Filing  
1/8/2014Robert BurrDirectorSell1,500$24.31$36,465.00View SEC Filing  
11/13/2013Robert BurrDirectorSell1,500$22.98$34,470.00View SEC Filing  
10/9/2013Robert BurrDirectorSell1,500$20.10$30,150.00View SEC Filing  
9/11/2013Robert BurrDirectorSell1,500$20.87$31,305.00View SEC Filing  
8/14/2013Robert BurrDirectorSell1,500$21.15$31,725.00View SEC Filing  
7/10/2013Robert L BurrDirectorSell1,500$20.26$30,390.00View SEC Filing  
6/12/2013Robert L BurrDirectorSell1,500$18.80$28,200.00View SEC Filing  
5/8/2013Robert L BurrDirectorSell1,500$16.35$24,525.00View SEC Filing  
5/1/2013Peter R TerreriDirectorSell3,450$17.39$59,995.50View SEC Filing  
3/12/2013Larry HsuCEOBuy7,000$16.88$118,160.00View SEC Filing  
3/12/2013Mark A SchlossbergSVPBuy1,000$16.73$16,730.00View SEC Filing  
2/13/2013Robert L BurrDirectorSell1,500$19.82$29,730.00View SEC Filing  
11/14/2012Robert L BurrDirectorSell1,500$19.86$29,790.00View SEC Filing  
8/20/2012Nigel FlemingDirectorSell6,000$23.99$143,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Impax Laboratories (NASDAQ:IPXL)
Latest Headlines for Impax Laboratories (NASDAQ:IPXL)
Source:
DateHeadline
americanbankingnews.com logoShort Interest in Impax Laboratories Inc (IPXL) Grows By 20.7%
www.americanbankingnews.com - May 26 at 7:10 AM
americanbankingnews.com logoMichael Nestor Sells 857 Shares of Impax Laboratories Inc (IPXL) Stock
www.americanbankingnews.com - May 17 at 4:52 PM
americanbankingnews.com logoMichael Nestor Sells 700 Shares of Impax Laboratories Inc (IPXL) Stock
www.americanbankingnews.com - May 15 at 10:57 PM
americanbankingnews.com logoImpax Laboratories Inc (IPXL) Sees Significant Growth in Short Interest
www.americanbankingnews.com - May 13 at 7:34 AM
finance.yahoo.com logoImpax Laboratories, Inc. :IPXL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 3:35 PM
americanbankingnews.com logoImpax Laboratories Inc (IPXL) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 12 at 10:37 AM
americanbankingnews.com logoRoyal Bank of Canada Reaffirms "Outperform" Rating for Impax Laboratories Inc (IPXL)
www.americanbankingnews.com - May 11 at 5:58 PM
finance.yahoo.com logoImpax Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 11 at 4:18 AM
finance.yahoo.com logoEdited Transcript of IPXL earnings conference call or presentation 10-May-17 12:30pm GMT
finance.yahoo.com - May 10 at 11:16 PM
americanbankingnews.com logoImpax Laboratories Inc (IPXL) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 3:32 PM
seekingalpha.com logoImpax Laboratories (IPXL) Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 1:15 PM
finance.yahoo.com logoInvestor Network: Impax Laboratories, Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 1:15 PM
feeds.benzinga.com logoTuring Rejects $100 Million Offer For Daraprim
feeds.benzinga.com - May 10 at 12:35 PM
americanbankingnews.com logoImpax Laboratories Inc (IPXL) Expected to Announce Quarterly Sales of $190.7 Million
www.americanbankingnews.com - May 10 at 12:33 PM
americanbankingnews.com logoImpax Laboratories Inc (IPXL) Issues FY17 Earnings Guidance
www.americanbankingnews.com - May 10 at 9:36 AM
marketbeat.com logoImpax Labs reports 1Q loss
marketbeat.com - May 10 at 5:19 AM
americanbankingnews.com logoImpax Laboratories Inc (IPXL) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 8 at 3:34 PM
americanbankingnews.com logoZacks: Brokerages Expect Impax Laboratories Inc (IPXL) to Post $0.11 Earnings Per Share
www.americanbankingnews.com - May 8 at 10:32 AM
americanbankingnews.com logoImpax Laboratories (IPXL) Getting Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - May 4 at 8:52 PM
americanbankingnews.com logoSomewhat Positive News Coverage Likely to Impact Impax Laboratories (IPXL) Share Price
www.americanbankingnews.com - April 30 at 6:05 PM
finance.yahoo.com logoImpax Announces FDA Approval and Launch of a Generic Version of Vytorin® (Ezetimibe/Simvastatin Tablets)
finance.yahoo.com - April 26 at 7:23 PM
finance.yahoo.com logoVetr Crowd Urges Sell For Impax Laboratories
finance.yahoo.com - April 25 at 10:40 AM
americanbankingnews.com logoVery Positive News Coverage Somewhat Likely to Affect Impax Laboratories (IPXL) Stock Price
www.americanbankingnews.com - April 24 at 9:36 AM
americanbankingnews.com logoSomewhat Favorable News Coverage Likely to Affect Impax Laboratories (IPXL) Share Price
www.americanbankingnews.com - April 21 at 10:11 PM
finance.yahoo.com logoImpax to Present Data on Rytary® (Carbidopa and Levodopa) Extended-Release Capsules, Zomig® (Zolmitriptan) …
finance.yahoo.com - April 21 at 10:37 AM
streetinsider.com logoImpax Laboratories (IPXL) to Present Data on Neurology Clinical Development Programs at AAN
www.streetinsider.com - April 21 at 10:37 AM
americanbankingnews.com logoImpax Laboratories Inc (IPXL) Expected to Announce Quarterly Sales of $201.8 Million
www.americanbankingnews.com - April 19 at 12:48 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Somewhat Likely to Affect Impax Laboratories (IPXL) Share Price
www.americanbankingnews.com - April 18 at 8:51 PM
americanbankingnews.com logoImpax Laboratories Inc (IPXL) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 17 at 12:12 PM
americanbankingnews.com logoZacks: Analysts Expect Impax Laboratories Inc (IPXL) to Post $0.14 Earnings Per Share
www.americanbankingnews.com - April 17 at 8:40 AM
americanbankingnews.com logoImpax Laboratories Inc (IPXL) Earns Hold Rating from Royal Bank of Canada
www.americanbankingnews.com - April 16 at 12:17 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Likely to Effect Impax Laboratories (IPXL) Share Price
www.americanbankingnews.com - April 15 at 4:25 PM
americanbankingnews.com logoShort Interest in Impax Laboratories Inc (IPXL) Rises By 49.0%
www.americanbankingnews.com - April 13 at 9:33 AM
americanbankingnews.com logoRoyal Bank of Canada Reiterates "Sector Perform" Rating for Impax Laboratories Inc (IPXL)
www.americanbankingnews.com - April 11 at 7:46 PM
americanbankingnews.com logoImpax Laboratories Inc (IPXL) Given a $10.00 Price Target by Royal Bank of Canada Analysts
www.americanbankingnews.com - April 10 at 12:04 AM
americanbankingnews.com logoImpax Laboratories Inc (IPXL) Given a $15.00 Price Target by Deutsche Bank AG Analysts
www.americanbankingnews.com - April 5 at 6:45 PM
americanbankingnews.com logoImpax Laboratories Inc (IPXL) Rating Reiterated by Royal Bank of Canada
www.americanbankingnews.com - April 2 at 8:54 PM
americanbankingnews.com logoImpax Laboratories Inc (IPXL) Stock Rating Reaffirmed by Royal Bank of Canada
www.americanbankingnews.com - April 2 at 7:54 PM
streetinsider.com logoImpax Laboratories (IPXL) Reports Favorable Ruling on Patent Validity for Zomig Nasal Spray - StreetInsider.com
www.streetinsider.com - March 31 at 7:49 AM
streetinsider.com logoImpax Laboratories (IPXL) Reports Favorable Ruling on Patent Validity for Zomig Nasal Spray
www.streetinsider.com - March 30 at 6:20 PM
capitalcube.com logoImpax Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : IPXL-US : March 28, 2017
us.rd.yahoo.com - March 28 at 11:06 AM
biz.yahoo.com logoIMPAX LABORATORIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement
us.rd.yahoo.com - March 28 at 11:06 AM
americanbankingnews.com logoImpax Laboratories Inc (IPXL) Earns Buy Rating from Guggenheim
www.americanbankingnews.com - March 27 at 6:27 PM
thestreet.com logoImpax Gains 38% On CEO Appointment, Talk of Sale
us.rd.yahoo.com - March 27 at 5:34 PM
biz.yahoo.com logoIMPAX LABORATORIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc.
us.rd.yahoo.com - March 27 at 5:34 PM
nasdaq.com logoImpax Laboratories Inc. (IPXL) Is Up Sharply After New CEO Named
www.nasdaq.com - March 27 at 10:54 AM
us.rd.yahoo.com logoImpax Board of Directors Appoints Paul M. Bisaro President and CEO
us.rd.yahoo.com - March 27 at 10:54 AM
americanbankingnews.com logoImpax Laboratories Inc (IPXL) Short Interest Down 32.3% in March
www.americanbankingnews.com - March 27 at 7:46 AM
americanbankingnews.com logoImpax Laboratories Inc (IPXL) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 21 at 11:40 AM
americanbankingnews.com logoImpax Laboratories (IPXL) – Analysts’ Weekly Ratings Changes
www.americanbankingnews.com - March 17 at 5:42 PM

Social

Chart

Impax Laboratories (IPXL) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff